Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

Emmanuel S. Antonarakis, MD1; Josep M. Piulats, MD, PhD2; Marine Gross-Goupil, MD, PhD3; Jeffrey Goh, MBBS4,5; Kristiina Ojamaa, MD6; Christopher J. Hoimes, DO7; Ulka Vaishampayan, MD8; Ranaan Berger, MD, PhD9; Ahmet Sezer, MD10; Tuomo Alanko, MD, PhD11; Ronald de Wit, MD, PhD12; Chunde Li, MD, PhD13; Aurelius Omlin, MD, PhD14; Giuseppe Procopio, MD15; Satoshi Fukasawa, MD16; Ken-ichi Tabata, MD, PhD17; Se Hoon Park, MD18; Susan Feyerabend, MD19; Charles G. Drake, MD, PhD20; Haiyan Wu, PhD21; Ping Qiu, PhD22; Jeri Kim, MD22; Christian Poehlein, MD22; and Johann Sebastian de Bono, MD, PhD23

abstract

PURPOSE Pembrolizumab has previously shown antitumor activity against programmed death ligand 1 (PD-L1)–positive metastatic castration-resistant prostate cancer (mCRPC). Here, we assessed the antitumor activity and safety of pembrolizumab in three parallel cohorts of a larger mCRPC population.

METHODS The phase II KEYNOTE-199 study included three cohorts of patients with mCRPC treated with docetaxel and one or more targeted endocrine therapies. Cohorts 1 and 2 enrolled patients with RECIST-measurable PD-L1–positive and PD-L1–negative disease, respectively. Cohort 3 enrolled patients with bone-predominant disease, regardless of PD-L1 expression. All patients received pembrolizumab 200 mg every 3 weeks for up to 35 cycles. The primary end point was objective response rate per RECIST v1.1 assessed by central review in cohorts 1 and 2. Secondary end points included disease control rate, duration of response, overall survival (OS), and safety.

RESULTS Two hundred fifty-eight patients were enrolled: 133 in cohort 1, 66 in cohort 2, and 59 in cohort 3. Objective response rate was 5% (95% CI, 2% to 11%) in cohort 1 and 3% (95% CI, <1% to 11%) in cohort 2. Median duration of response was not reached (range, 1.9 to ≥21.8 months) and 10.6 months (range, 4.4 to 16.8 months), respectively. Disease control rate was 10% in cohort 1, 9% in cohort 2, and 22% in cohort 3. Median OS was 9.5 months in cohort 1, 7.9 months in cohort 2, and 14.1 months in cohort 3. Treatment-related adverse events occurred in 60% of patients, were of grade 3 to 5 severity in 15%, and led to discontinuation of treatment in 5%.

CONCLUSION Pembrolizumab monotherapy shows antitumor activity with an acceptable safety profile in a subset of patients with RECIST-measurable and bone-predominant mCRPC previously treated with docetaxel and targeted endocrine therapy. Observed responses seem to be durable, and OS estimates are encouraging.

J Clin Oncol 37. © 2019 by American Society of Clinical Oncology

INTRODUCTION

In the past decade, therapeutic options for advanced prostate cancer have increased secondary to improved understanding of the molecular mechanisms that underlie metastatic progression, including the critical role of the tumor microenvironment.1 Metastatic prostate cancer initially responds to androgen deprivation, the long-standing standard of care. More recent trials have shown that adding docetaxel2-4 or abiraterone acetate5,6 to androgen deprivation improves overall survival (OS) in patients with metastatic hormone-sensitive disease. Eventually, tumors stop responding to androgen deprivation, a state referred to as castrate-resistant prostate cancer (CRPC).7 For patients with metastatic CRPC (mCRPC), treatment options that confer a survival benefit include docetaxel8,9 cabazitaxel,10 abiraterone,11,12 enzalutamide,13,14 sipuleucel-T15 and the bone-specific radionuclide radium-223.16 These therapies are not curative and may be associated with poor tolerability.

Monoclonal antibodies that target cytotoxic T-lymphocyte–associated protein 4, programmed death 1 receptor (PD-1), and programmed death ligand 1 (PD-L1) have demonstrated antitumor activity and manageable safety in several advanced malignancies. Although checkpoint inhibition has demonstrated efficacy in urothelial and renal-cell carcinomas,17-20 prostate cancer has a more immunosuppressive microenvironment than these
other genitourinary malignancies,\textsuperscript{26–28} which suggests that mCRPC may be less susceptible to immune checkpoint blockade. The cytotoxic T-lymphocyte–associated protein 4 inhibitor ipilimumab failed to significantly prolong OS in patients with mCRPC that progressed on docetaxel\textsuperscript{29} or was chemotherapy naive.\textsuperscript{30} Recently, the humanized, anti–PD-1 monoclonal antibody pembrolizumab has demonstrated antitumor activity and manageable safety in patients with mCRPC. In 23 patients with PD-L1–positive mCRPC who were enrolled in KEYNOTE-028, three quarters of whom had received two or more lines of previous therapy, pembrolizumab provided a 17% objective response rate (ORR), a 30% disease control rate (DCR), and a 37% estimated 12-month OS rate.\textsuperscript{31} Initial results from the first 10 patients with enzalutamide-resistant mCRPC who were treated with pembrolizumab in a phase II study showed a rapid decrease in prostate–specific antigen (PSA) levels for three patients, radiographic partial response in two patients, and radiographic stable disease in three patients.\textsuperscript{32}

To further explore the antitumor activity and safety of pembrolizumab in mCRPC, we performed the KEYNOTE-199 study. We report results for the first three cohorts, which enrolled in parallel and included patients who previously received docetaxel and targeted endocrine therapy for disease that was measurable and PD-L1 positive (cohort 1) or negative (cohort 2) or that was bone predominant, regardless of PD-L1 status (cohort 3).

\section*{METHODS}

\subsection*{Study Design and Patients}

KEYNOTE-199 is a five-cohort, open-label, phase II study. Cohorts 1, 2, and 3 enrolled patients at 85 sites in 21 countries. The trial was conducted in accordance with Good Clinical Practice and the protocol and its amendments, which were approved by the appropriate ethics body at each center. All patients provided written informed consent.

Key eligibility criteria for cohorts 1 to 3 included age 18 years or older; metastatic or locally confined but inoperable, pathologically confirmed prostate adenocarcinoma; measurable disease per RECIST v1.1\textsuperscript{33} (cohorts 1 and 2) or detectable bone metastases by whole-body bone scintigraphy and no RECIST-measurable tumors (cohort 3) by central review; Eastern Cooperative Oncology Group performance status 0, 1, or 2; provision of a tumor sample for PD-L1 assessment (cohort 1 limited to PD-L1–positive disease, cohort 2 limited to PD-L1–negative disease); and previous treatment with one or more targeted endocrine therapies and one to two chemotherapy regimens, one of which must have included docetaxel. Full inclusion and exclusion criteria are in the protocol (available in the Data Supplement).

\subsection*{Treatment}

Pembrolizumab 200 mg was administered intravenously every 3 weeks until disease progression, intolerable toxicity, physician decision, withdrawal of consent, or a maximum of 35 cycles was reached. Patients with confirmed complete response who received eight or more pembrolizumab cycles, including two or more cycles beyond initial complete response, were permitted to discontinue treatment. Complete discontinuation criteria and adverse event (AE) management guidelines are available in the protocol.

\section*{Assessments and End Points}

PD-L1 expression was assessed at a central laboratory in formalin-fixed, paraffin-embedded tumor samples using the PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies, Carpinteria, CA). Patients in cohorts 1 and 2 were required to provide biopsy samples from metastatic tumor collected within 12 months of screening or an archival tumor specimen if collection from a metastasis was not feasible. Patients in cohort 3 were required to provide at least an archival specimen. PD-L1 positivity was defined as a combined positive score (CPS) of \( \geq 1 \), where CPS is the number of PD-L1–positive cells—tumor cells, lymphocytes, and macrophages—divided by the total number of tumor cells \( \times 100 \). Mutations in DNA damage repair (DDR) genes were interrogated using whole-exome sequencing of DNA isolated from formalin-fixed, paraffin-embedded tumor samples. Complete details are found in the Data Supplement.

Computed tomography, radionuclide bone scanning, and PSA assessment were performed at baseline, every 9 weeks during year 1, and every 12 weeks thereafter. AEs were collected throughout treatment and for 30 days thereafter—90 days for serious AEs—and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Survival was assessed every 12 weeks during follow-up.

The primary end point was ORR per RECIST v1.1, assessed by central review in patients with measurable disease at baseline in cohorts 1 and 2 separately and combined. Secondary end points included DCR per RECIST v1.1, assessed by central review; ORR, DCR, and radiographic progression-free survival (rPFS) per Prostate Cancer Working Group 3 (PCWG3)–modified RECIST v1.1,\textsuperscript{34} assessed by central review; PSA response rate, and OS in cohorts 1 and 2 combined, cohorts 1, 2, and 3 combined, and each cohort separately; duration of response per RECIST v1.1 and per PCWG3-modified RECIST v1.1, assessed by central review for cohorts 1 and 2 combined and separately; and safety and tolerability. Detailed end point definitions are provided in the Data Supplement.

\section*{Statistical Considerations}

The statistical analysis plan is available in the protocol in the Data Supplement. Antitumor activity and safety were analyzed in all patients who received one or more pembrolizumab doses. Patients without a baseline PSA level were excluded from PSA response analysis. ORR, DCR, and PSA response rate point estimates and 95\% CIs were...
calculated using the Clopper-Pearson exact binomial method. rPFS, OS, and response duration were estimated using the Kaplan-Meier method; censoring rules for time-to-event end points are summarized in the Data Supplement. No hypothesis testing was planned, and no multiplicity adjustments to control for Type I error were performed. The planned sample size was approximately 200 patients in cohorts 1 and 2 combined and 50 patients in cohort 3 and was designed to provide a 95% CI for ORR with an approximate width of 10%.

RESULTS

Patients

Between July 1, 2016, and March 31, 2017, 260 of 394 patients who were screened for cohorts 1, 2, and 3 were enrolled (Fig 1). Cohort 1 included 133 patients with RECIST-measurable, PD-L1–positive disease. Cohort 2 included 65 patients with RECIST-measurable, PD-L1–negative disease and three patients with RECIST-measurable disease of unknown PD-L1 status. Cohort 3 included 59 patients with bone-predominant disease. Biopsy samples that were adequate for PD-L1 testing were acquired within 12 months of screening for 122 (92%) of 133 patients in cohort 1 and 52 (79%) of 66 in cohort 2. These newly collected samples were from metastases in 98 (80%) of 122 and 48 (92%) of 52 patients, respectively. In cohort 3, two (9%) of 23 PD-L1–negative samples were acquired within 12 months of screening; only one newly collected sample, which was PD-L1 negative, was from a metastasis.

Baseline characteristics were generally as expected for a docetaxel-treated mCRPC population (Table 1). Across cohorts, median age was 68 years, 36% of patients had Eastern Cooperative Oncology Group performance status 0, 29% received two or more previous chemotherapy regimens, and 25% received two or more previous antiandrogen therapies. Median PSA level in cohorts 1, 2, and 3 was 115.5 ng/mL, 116.1 ng/mL, and 43.3 ng/mL, respectively.

As of the August 21, 2018, data cutoff, median follow-up was 9.5 months in cohort 1, 7.9 months in cohort 2, and 14.1 months in cohort 3, and 4%, 0%, and 3% of patients, respectively, remained on pembrolizumab (Fig 1). All but two patients in cohort 2 received one or more pembrolizumab doses. The most common reasons for treatment discontinuation were disease progression and AEs. Median treatment duration was 2.1 months (range, 0.03 to 21.4 months) in cohort 1, 1.6 months (range, 0.03 to 18.7 months) in cohort 2, and 3.2 months (range, 0.7 to 21.9 months) in cohort 3.

Antitumor Activity

Among the 199 patients in cohorts 1 and 2, 29% had a decrease from baseline in the sum of target lesions, including 9% who had a 30% or greater decrease; 26% of patients had no change or a less than 20% increase in the sum of target lesions, with similar results in each cohort (Fig 2A). Considering only the 166 patients with one or more evaluable postbaseline imaging assessment, 34% had any decrease, 10% had a 30% or greater decrease, and 31% had no change or a less than 20% increase in the sum of target lesions. ORR was 5% (95% CI, 2% to 11%) in cohort 1, 3% (95% CI, < 1% to 11%) in cohort 2, and 5% (95% CI, 2% to 8%) in cohorts 1 and 2 combined, per both RECIST v1.1 and PCWG3-modified RECIST (Table 2). Two patients, both in cohort 1, achieved a complete radiographic response. The remaining five responses in cohort 1...
and both responses in cohort 2 were partial responses (Appendix Table A1, online only). Per RECIST v1.1, an additional six patients in cohort 1 and four patients in cohort 2 had stable disease for 6 months or longer leading to a DCR of 10% and 9%, respectively (Table 2). DCR per PCWG3-modified RECIST was 13% in cohort 1, 18% in cohort 2, 39% in cohort 3, 15% in cohorts 1 and 2 combined, and 20% in cohorts 1, 2, and 3 combined (Table 2). Among the nine patients with radiographic response, four remained on treatment at data cutoff, three had experienced subsequent disease progression, and one had died without disease progression (Fig 3A). Median response duration was not reached (range, 1.9 to ≥ 21.8 months) in cohort 1, was 10.6 months (range, 4.4 to 16.8 months) in cohort 2, and was 16.8 months (range, 1.9 to ≥ 21.8 months) in cohorts 1 and 2 combined per both RECIST v1.1 and PCWG3-modified RECIST.

Median rPFS per PCWG3-modified RECIST was 2.1 months (95% CI, 2.0 to 2.1 months) in cohort 1, 2.1 months (95% CI, 2.0 to 3.3 months) in cohort 2, and 3.7 months (95% CI, 2.1 to 4.2 months) in cohort 3 (Fig 3B). Median OS was 9.5 months (95% CI, 6.4 to 11.9 months) in cohort 1, 7.9 months (95% CI, 5.9 to 10.2 months) in cohort 2, and 14.1 months (95% CI, 10.8 to 17.6 months) in cohort 3 (Fig 3C). Estimated 12-month survival rates were 41%, 35%, and 62%, respectively. In cohorts 1 and 2 combined, median rPFS was 2.1 months (95% CI, 2.0 to 2.1 months) and median OS was 8.1 months (95% CI, 6.6 to 10.7 months). Median rPFS and OS were 2.1 months (95% CI, 2.1 to 2.2 months) and 9.6 months (95% CI, 7.9 to 12.2 months), respectively, in cohorts 1, 2, and 3 combined.

Of 243 patients in cohorts 1, 2, and 3 with baseline PSA assessment, 15% experienced some decrease in PSA level, including 9% who had a 50% or greater decrease and 5% who had a 90% or greater decrease (Fig 2B). Stable PSA levels were observed in 9% of patients. Confirmed PSA responses occurred in 6% of 124 patients in cohort 1, 8% of 60 in cohort 2, 2% of 59 in cohort 3, 7% of 184 in cohorts 1 and 2 combined, and 6% of 243 in cohorts 1, 2, and 3 combined (Table 2).

**Exploratory Biomarker Analysis**

Across cohorts, 153 of 258 patients, including six of nine with complete or partial response, had tumor samples for

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Cohort 1</th>
<th>Cohort 2</th>
<th>Cohort 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age, years (range)</td>
<td>68 (48-85)</td>
<td>68 (53-84)</td>
<td>71 (53-90)</td>
</tr>
<tr>
<td>ECOG performance status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>42 (32)</td>
<td>25 (38)</td>
<td>26 (44)</td>
</tr>
<tr>
<td>1</td>
<td>75 (56)</td>
<td>36 (55)</td>
<td>27 (46)</td>
</tr>
<tr>
<td>2</td>
<td>16 (12)</td>
<td>4 (6)</td>
<td>6 (10)</td>
</tr>
<tr>
<td>Missing</td>
<td>0</td>
<td>1 (2)</td>
<td>0</td>
</tr>
<tr>
<td>Gleason score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 7</td>
<td>40 (31)</td>
<td>18 (27)</td>
<td>24 (41)</td>
</tr>
<tr>
<td>≥ 8</td>
<td>85 (64)</td>
<td>43 (65)</td>
<td>32 (54)</td>
</tr>
<tr>
<td>Unknown</td>
<td>8 (6)</td>
<td>5 (8)</td>
<td>3 (5)</td>
</tr>
<tr>
<td>Median PSA value, ng/mL (range)</td>
<td>115.5 (0.1-5,000.0)</td>
<td>116.1 (1.0-3,583.0)</td>
<td>43.3 (0.1-2,539.0)</td>
</tr>
<tr>
<td>Presence of visceral disease</td>
<td>89 (67)</td>
<td>30 (45)</td>
<td>6 (10)</td>
</tr>
<tr>
<td>No. of previous chemotherapy regimens</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>89 (67)</td>
<td>48 (73)</td>
<td>46 (78)</td>
</tr>
<tr>
<td>≥ 2</td>
<td>44 (33)</td>
<td>18 (27)</td>
<td>13 (22)</td>
</tr>
<tr>
<td>Types of previous targeted endocrine therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enzalutamide only</td>
<td>41 (31)</td>
<td>27 (41)</td>
<td>16 (27)</td>
</tr>
<tr>
<td>Abiraterone only</td>
<td>57 (43)</td>
<td>24 (36)</td>
<td>28 (47)</td>
</tr>
<tr>
<td>Enzalutamide and abiraterone</td>
<td>34 (26)</td>
<td>15 (23)</td>
<td>15 (25)</td>
</tr>
<tr>
<td>Other</td>
<td>1 (&lt; 1)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

**NOTE.** Data are presented as No. (%) unless otherwise indicated. Abbreviations: ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed death-ligand 1; PSA, prostate-specific antigen.
which whole-exome sequencing was completed. Of these, 19 (12%) had aberrations in \textit{BRCA1/2} or \textit{ATM} and 10 (7%) had aberrations in one or more of 12 other homologous recombination repair (HRR) genes (overall prevalence, 19%; Appendix Table A2, online only). None of the six patients who experienced a response and had evaluable genomic data were determined to have microsatellite instability as defined by the mSINGS assay. ORR per RECIST v1.1 by central review was 11% in patients with \textit{BRCA1/2} or \textit{ATM} aberrations, 0% in patients with aberrations in one or more of the 12 other HRR genes, and 3% in patients without any HRR gene aberrations (Appendix Table A2). Response duration was 4.4 months in the patient with a \textit{ATM} mutation and \text{\textguillemet} 21.8 months in the patient with a \textit{BRCA2} mutation. Among the four responders without aberrations in HRR genes, response duration ranged from 1.9 months to \text{\textguillemet} 16.6 months. Dedicated examination of 50 DDR genes in the six evaluable objective responders revealed that four patients had somatic aberrations in one or more of the genes evaluated (Appendix Table A3, online only). Local biomarker testing of two responding patients whose responses lasted more than 2 years revealed a mismatch repair defect by immunohistochemistry that was below the cutoff for high microsatellite instability by mSINGS with high tumor mutational burden and high CD3 intratumor infiltration in one patient and an amplified \textit{CD274} (PD-L1)/\textit{PDCD1LG2} (PD-L2) locus in the other.

**Safety**

Across cohorts, 155 (60%) patients experienced one or more treatment-related AEs, including 39 (15%) with one or more grade 3 to 5 treatment-related AEs and 12 (5%) who discontinued pembrolizumab because of a treatment-related AE. Two patients died of AEs that were considered to be treatment related by the investigator (pneumonitis and...
performed nonprogressive disease for 6 months or longer. Patients who died after month 6 without evidence of disease progression before death were considered to have stable disease for 6 months or longer.

**DISCUSSION**

In this multicohort, open-label, phase II study, which to our knowledge is the largest trial of anti–PD-1 therapy in mCRPC conducted to date, we showed that pembrolizumab monotherapy has antitumor activity in patients with mCRPC previously treated with docetaxel and one or more targeted endocrine therapies, with approximately 25% of patients having received both enzalutamide and abiraterone. Observed OS estimates are promising, suggesting that immunotherapy may be able to extend the tail of the survival curve in a historically difficult-to-treat population. Pembrolizumab demonstrated activity in both RECIST-measurable and bone-predominant disease, as well as in PD-L1–positive and PD-L1–negative tumors. Although there was only one PSA response in cohort 3, rPFS and OS were longer than in cohorts 1 and 2, reflecting different prognoses of bone-predominant and RECIST-measurable disease. Pembrolizumab had manageable safety, and the overall toxicity profile was consistent with that previously observed for pembrolizumab.

Although the observed ORR was a modest 5%, those responses that did occur were durable. Among the nine patients with RECIST-measurable disease who achieved complete or partial response, five had response ongoing at data cutoff, and median duration was 16.8 months. The prolonged response durability is consistent with what has been previously observed for pembrolizumab in other tumor types. To capture antitumor activity in bone metastases, which occur in 60% to 70% of men with advanced prostate cancer, this study also applied PCWG3-modified response assessment. Whereas ORR and response duration in cohorts 1 and 2 were similar regardless of the criteria applied, DCR was higher in all cohorts using PCWG3-modified RECIST. These findings highlight the importance of accurately evaluating progression in bone metastases and suggest that PCWG3-modified RECIST may be preferable for assessing antitumor activity in mCRPC.

This study showed a clear signal of antitumor activity for pembrolizumab monotherapy in a small number of patients with RECIST-measurable and bone-predominant disease, as well as in PD-L1–positive and PD-L1–negative tumors. Although there was only one PSA response in cohort 3, rPFS and OS were longer than in cohorts 1 and 2, reflecting different prognoses of bone-predominant and RECIST-measurable disease. Pembrolizumab had manageable safety, and the overall toxicity profile was consistent with that previously observed for pembrolizumab.

Although the observed ORR was a modest 5%, those responses that did occur were durable. Among the nine patients with RECIST-measurable disease who achieved complete or partial response, five had response ongoing at data cutoff, and median duration was 16.8 months. The prolonged response durability is consistent with what has been previously observed for pembrolizumab in other tumor types. To capture antitumor activity in bone metastases, which occur in 60% to 70% of men with advanced prostate cancer, this study also applied PCWG3-modified response assessment. Whereas ORR and response duration in cohorts 1 and 2 were similar regardless of the criteria applied, DCR was higher in all cohorts using PCWG3-modified RECIST. These findings highlight the importance of accurately evaluating progression in bone metastases and suggest that PCWG3-modified RECIST may be preferable for assessing antitumor activity in mCRPC.

**TABLE 2. Summary of Responses**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Cohort 1 (PD-L1 positive)</th>
<th>Cohort 2 (PD-L1 negative)</th>
<th>Cohort 3 (bone predominant)</th>
<th>Cohorts 1 and 2 Combined</th>
<th>Cohorts 1, 2, and 3 Combined</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Response assessed per RECIST v1.1 by central radiology review</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>No. of patients</strong></td>
<td>133</td>
<td>66</td>
<td>59</td>
<td>199</td>
<td>258</td>
</tr>
<tr>
<td><strong>ORR, No. (%; 95% CI)</strong></td>
<td>7 (5; 2 to 11)</td>
<td>2 (3; &lt; 1 to 11)</td>
<td>—</td>
<td>9 (5; 2 to 8)</td>
<td>—</td>
</tr>
<tr>
<td><em><em>DCR,</em> No. (%; 95% CI)</em>*</td>
<td>13 (10; 5 to 16)</td>
<td>6 (9; 3 to 19)</td>
<td>13 (22; 12 to 35)</td>
<td>19 (10; 6 to 15)</td>
<td>32 (12; 9 to 17)</td>
</tr>
<tr>
<td><strong>Response assessed per PCWG3-modified RECIST v1.1 by central radiology review</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>No. of patients</strong></td>
<td>133</td>
<td>66</td>
<td>59</td>
<td>199</td>
<td>258</td>
</tr>
<tr>
<td><strong>ORR, No. (%; 95% CI)</strong></td>
<td>7 (5; 2 to 11)</td>
<td>2 (3; &lt; 1 to 11)</td>
<td>—</td>
<td>9 (5; 2 to 8)</td>
<td>—</td>
</tr>
<tr>
<td><em><em>DCR,</em> No. (%; 95% CI)</em>*</td>
<td>17 (13; 8 to 20)</td>
<td>12 (18; 10 to 30)</td>
<td>23 (39; 27 to 53)</td>
<td>29 (15; 10 to 20)</td>
<td>52 (20; 15 to 26)</td>
</tr>
<tr>
<td><strong>PSA response† in patients with baseline PSA measurement</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>No. of patients</strong></td>
<td>124</td>
<td>60</td>
<td>59</td>
<td>184</td>
<td>243</td>
</tr>
<tr>
<td><strong>Response rate, No. (%; 95% CI)</strong></td>
<td>8 (6; 3 to 12)</td>
<td>5 (8; 3 to 18)</td>
<td>1 (2; 0 to 9)</td>
<td>13 (7; 4 to 12)</td>
<td>14 (6; 3 to 10)</td>
</tr>
</tbody>
</table>

Abbreviations: DCR, disease control rate; ORR, objective response rate; PCWG3, Prostate Cancer Working Group 3; PD-L1, programmed death-ligand 1; PSA, prostate-specific antigen.

†Defined as the percentage of patients with a reduction in PSA level from baseline by 50% or greater as confirmed on an additional PSA evaluation performed ≥ 3 weeks later.
patients with previously treated mCRPC, which highlights the importance of identifying predictive biomarkers. Exploratory biomarker analysis did not seem to identify a clear relationship between response to pembrolizumab and mutations in DDR genes as determined by whole-exome sequencing. The contemporaneous presence of mismatch repair defects could not be excluded, and orthogonal assay testing beyond next-generation sequencing would be necessary to determine functional loss. Although there was no protocol-specified hypothesis testing, outcomes were similar in patients with PD-L1–positive and –negative disease using CPS ≥ 1 to define positivity. Biomarker analyses were limited by the low number of responses and the availability of whole-exome sequencing results from only a fraction of the population. Ongoing and future biomarker studies from KEYNOTE-199, including exploration of different CPS cut points, gene expression profiles, and tumor mutational burden, will aim to uncover molecular markers of response to single-agent pembrolizumab. Because the mSINGS assay may provide false negatives, additional assessment of microsatellite instability is also ongoing. Prospective trials would be required to assess

FIG 3. Antitumor activity. (A) Swimmer plot of patients with confirmed response as assessed by Prostate Cancer Working Group 3 (PCWG3)–modified RECIST v1.1 per central review in cohorts 1 (n = 7) and 2 (n = 2) or with stable disease or noncomplete response/nonprogressive disease of 6 or more months duration in cohorts 1 (n = 10), 2 (n = 10), and 3 (n = 23). Patients who died after month 6 without evidence of disease progression before death were considered to have stable disease for 6 months or longer. The end of the bar indicates the time to the last imaging assessment. (B) Kaplan-Meier estimates of radiographic progression-free survival (rPFS) as assessed by PCWG3-modified RECIST v1.1 per central review in cohorts 1 (n = 133), 2 (n = 66), and 3 (n = 59). (C) Kaplan-Meier estimates of overall survival (OS) in cohorts 1, 2, and 3.
the relationship between DNA repair defects of interest and antitumor activity. These data add to the growing body of evidence that suggests that, despite its more immunosuppressive microenvironment, a small number of select patients with mCRPC may benefit from pembrolizumab.\textsuperscript{31,32} Data from KEYNOTE-199 cohorts 4 and 5 are pending and will help determine whether pembrolizumab monotherapy has activity in patients with RECIST-measurable (cohort 4) and bone-predominant (cohort 5) chemotherapy-naive mCRPC receiving ongoing enzalutamide treatment. Initial evidence of pembrolizumab monotherapy activity has led to several studies of PD-1 inhibitor-based combination regimens in mCRPC. Data from the multicohort, phase Ib/II KEYNOTE-365...
study demonstrated promising antitumor activity and manageable safety for combinations of pembrolizumab with olaparib,\textsuperscript{44} docetaxel,\textsuperscript{45} and enzalutamide.\textsuperscript{46} Data from the final KEYNOTE-365 cohort of pembrolizumab plus abiraterone and prednisone are pending (ClinicalTrials.gov identifier: NCT02861573). Beyond pembrolizumab and as suggested by an earlier, smaller study,\textsuperscript{47} the phase II CheckMate 650 study showed promising antitumor activity for the combination of nivolumab and ipilimumab in men with mCRPC, although toxicity was a concern and there was a suggestion that prior taxane therapy was associated with lower ORR.\textsuperscript{48} Several phase III studies of pembrolizumab in mCRPC that evaluate response on the basis of PCWG3-modified RECIST are ongoing.

This study has several limitations, including the lack of randomization, lack of a control arm, and relatively short follow-up. Because of the inherent biology of metastatic prostate cancer with its tropism to bone, only a proportion of patients provided biopsy samples that could be subjected to whole-exome DNA sequencing. Therefore, the ability to fully characterize the genetic landscape and identify molecular markers of response to pembrolizumab was limited.

In conclusion, pembrolizumab monotherapy shows antitumor activity and disease control with an acceptable safety profile in subsets of patients with RECIST-measurable or bone-predominant mCRPC previously treated with docetaxel and targeted endocrine therapy. Responses seem to be durable, and the observed OS benefit is encouraging.
REFERENCES

42. Antonarakis ES: A new molecular taxonomy to predict immune checkpoint inhibitor sensitivity in prostate cancer. Oncologist 24:430-432, 2019
45. Massard C, Retz M, Hammerer P, et al: KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC). J Clin Oncol 37, 2019 (supple 7S; abstr 170)
46. Fong PCC, Retz M, Drakaki A, et al: KEYNOTE-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC). J Clin Oncol 37, 2019 (suppl 7S; abstr 171)
AUTORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/wc or ascopubs.org/jco/site/ifc.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Emmanuel S. Antonarakis
Honorsia: Sanofi, Dendreon, Medivation, Janssen Biotech, ESSA, Astellas Pharma, MSD, AstraZeneca, Clovis Oncology
Research Funding: Janssen Biotech (Inst), Johnson & Johnson (Inst), Sanofi (Inst), Dendreon (Inst), Aragon Pharmaceuticals (Inst), Exelixis (Inst), Millennium Pharmaceuticals (Inst), Genentech (Inst), Novartis (Inst), Astellas Pharma (Inst), Tokai Pharmaceutical (Inst), MSD (Inst), AstraZeneca (Inst), Clovis Oncology (Inst), Constellation Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property: Coinventor of a biomarker technology licensed to Qiagen
Travel, Accommodations, Expenses: Sanofi, Dendreon, Medivation

Josep M. Piulats
Consulting or Advisory Role: Janssen Oncology, Astellas Pharma, VCN Biosciences, Clovis Oncology, Genentech, Bristol-Myers Squibb, MSD
Research Funding: Bristol-Myers Squibb, AstraZeneca, MedImmune, MSD, Pfizer, EMD Serono, Incyte, Janssen Oncology
Travel, Accommodations, Expenses: Amgen, Roche, Bristol-Myers Squibb

Marine Gross-Goupil
Honorsia: Ipsen, Janssen-Cilag, Sanofi
Consulting or Advisory Role: Bristol-Myers Squibb, MSD, Pfizer, Ipsen, Roche
Research Funding: Pfizer, MSD, Roche, Ipsen, Janssen-Cilag
Travel, Accommodations, Expenses: Amgen, Roche, Ipsen, MSD

Jeffrey Goh
Stock and Other Ownership Interests: ImmuneP
Research Funding: MSD (Inst)
Consulting or Advisory Role: Tesaro, AstraZeneca
Speakers: Bureau: Novartis, Ipsen, Jansen, Mundipharma
Travel, Accommodations, Expenses: Astellas Pharma, AstraZeneca

Kristiina Ojamaa
Consulting or Advisory Role: AstraZeneca
Research Funding: MSD (Inst)

Christopher J. Hoimes
Honorsia: Seattle Genetics
Consulting or Advisory Role: Foundation Medicine, Bristol-Myers Squibb, Eisai, Prometheus Laboratories, Seattle Genetics, Genentech, MSD, 2biPrecise
Speakers’ Bureau: Bristol-Myers Squibb, Genentech
Research Funding: MSD, MSD (Inst)

Ulka Vaishampayan
Honorsia: Pfizer, Bayer, Sanofi, Bristol-Myers Squibb, Exelixis
Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, Exelixis, Bayer, EMD Serono
Speakers’ Bureau: Pfizer, Bayer, Bristol-Myers Squibb, Exelixis, Sanofi, Eisai
Research Funding: Astellas Pharma, Exelixis, Pfizer, Bristol-Myers Squibb, MSD (Inst)

Raanan Berger
Stock and Other Ownership Interests: Mitra Biotech, Belong
Honorsia: Mitra Biotech, Bristol-Myers Squibb, Roche, AstraZeneca, Pfizer, MSD Oncology
Consulting or Advisory Role: Mitra Biotech, Belong, MSD, Bristol-Myers Squibb
Speakers’ Bureau: Mitra Biotech, Bristol-Myers Squibb, MSD
Travel, Accommodations, Expenses: Mitra Biotech, Bristol-Myers Squibb, AstraZeneca

Ahmet Sezer
Honorsia: Pfizer (Inst), Roche (Inst), Amgen (Inst)
Speakers’ Bureau: Roche, Pfizer, Amgen, Bristol-Myers Squibb
Research Funding: Regeneron (Inst), MSD (Inst), Pfizer (Inst), Novartis (Inst), Merck Serono (Inst), Novartis (Inst)
Travel, Accommodations, Expenses: Amgen, Bristol-Myers Squibb, Roche

Tuomo Alanko
Consulting or Advisory Role: Amgen, Bayer, Baxalta, Shire, Bristol-Myers Squibb, Celgene, Eli Lilly, MSD, Netmedii, Nordic Drugs, Roche
Research Funding: AbbVie (Inst), Bayer (Inst), Boehringer Ingelheim (Inst), Bristol-Myers Squibb (Inst), Eli Lilly (Inst), Incyte (Inst), MSD (Inst), Pfizer (Inst), Roche (Inst)
Travel, Accommodations, Expenses: Baxalta, Shire, Bristol-Myers Squibb, MSD, Pfizer, Roche

Ronald de Wit
Honorsia: Sanofi, MSD
Consulting or Advisory Role: Sanofi, MSD, Genentech, Janssen, Bayer, Clovis
Research Funding: Sanofi (Inst), Bayer (Inst), MSD (Inst)
Travel, Accommodations, Expenses: Eli Lilly

Chunde Li
Stock and Other Ownership Interests: Chundsell Medicals
Research Funding: MSD (Inst)
Patents, Royalties, Other Intellectual Property: Royalty agreement with Chundsell Medicals on the basis of a patent granted in Sweden and pending for grant internationally

Aurelius Omlin
Consulting or Advisory Role: Astellas Pharma (Inst), Bayer (Inst), Sanofi (Inst), Roche (Inst), Janssen (Inst), MSD (Inst), Molecular Partners (Inst)
Research Funding: Teva (Inst), Janssen (Inst), MSD (Inst)
Travel, Accommodations, Expenses: Sanofi, Bayer, Astellas Pharma, Janssen

Giuseppe Procopio
Consulting or Advisory Role: Bayer, Bristol-Myers Squibb, Janssen, Novartis, Astellas Pharma, Pfizer, Ipsen, MSD
Research Funding: MSD (Inst)

Satoshi Fukasawa
Honorsia: Ono Pharmaceutical, Bristol-Myers Squibb, MSD, Astellas Pharma, AstraZeneca, Novartis, Pfizer, Janssen, Takeda, Daiichi Sankyo
Consulting or Advisory Role: AstraZeneca
Research Funding: MSD (Inst)

Se Hoon Park
Consulting or Advisory Role: Eli Lilly
Research Funding: MSD (Inst)

Susan Feyerabend
Research Funding: MSD (Inst)
Consulting or Advisory Role: Janssen-Cilag, Astellas Pharma

Charles G. Drake
Stock and Other Ownership Interests: Compugen, Tizona Therapeutics, Harpoon Therapeutics, Kio Pharmaceuticals
Consulting or Advisory Role: AstraZeneca, MedImmune, Bristol-Myers Squibb, Compugen, Genentech, Janssen Oncology, Pfizer, Tizona Therapeutics, Potenza Therapeutics, MSD, Pierre Fabre
Research Funding: Bristol-Myers Squibb (Inst), MSD (Inst)
Patents, Royalties, Other Intellectual Property: Patents licensed to Bristol-Myers Squibb (Inst), Patents licensed to Potenza Therapeutics (Inst)
Travel, Accommodations, Expenses: Genentech, American Association for Cancer Research, American Society of Clinical Oncology, MSD, Pfizer

Haiyan Wu
Employment: MSD
Stock and Other Ownership Interests: MSD (I)

Ping Gii
Employment: MSD

Jeiy Kim
Employment: MSD
Stock and Other Ownership Interests: MSD

Christian Poehlein
Employment: MSD
Leadership: MSD

Stock and Other Ownership Interests: MSD
Johann Sebastian de Bono

Honoraria: AstraZeneca, Sanofi, Astellas Pharma, Pfizer, Genentech, Janssen Oncology, Menarini Silicon Biosystems, Daiichi Sankyo, Sierra Oncology, Bioexcel

Consulting or Advisory Role: AstraZeneca, Sanofi, Genentech, Astellas Pharma, Bayer, Pfizer, Merck Sharp & Dohme, Merck Serono, Boehringer Ingelheim, Sierra Oncology, Menarini Silicon Biosystems, Celgene, Taiho Pharmaceutical, Daiichi Sankyo, Janssen Oncology, Genmab, GlaxoSmithKline, Orion Pharma, Eisai, BioXCell Therapeutics

Research Funding: AstraZeneca (Inst), Genentech (Inst), Sanofi (Inst), Taiho Pharmaceutical (Inst), Daiichi Sankyo (Inst), Merck Serono (Inst), Astex Pharmaceuticals (Inst), Merck Sharp & Dohme (Inst), Orion Pharma (Inst), GlaxoSmithKline (Inst), CellCentric (Inst), Celgene (Inst), Sierra Oncology (Inst), Bayer (Inst), MedImmune (Inst), Medivation (Inst)

Patents, Royalties, Other Intellectual Property: Abiraterone rewards to inventors (Inst), PARP inhibitors and DNA repair defects (Inst), Targeting of IL-23 in prostate cancer (Inst), CHK1 inhibitor (Inst)

Travel, Accommodations, Expenses: AstraZeneca, Astellas Pharma, GlaxoSmithKline, Orion Pharma, Sanofi, Genmab, Taiho Pharmaceutical, Qiagen, Vertex

No other potential conflicts of interest were reported.
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

Emmanuel S. Antonarakis, Josep M. Picluts, Marine Gross-Goupil, Jeffrey Goh, Kristina Ojamaa, Christopher J. Hoimes, Ulika Vaishampayan, Ranaan Berger, Ahmet Sezer, Tuomo Alanko, Ronald de Wit, Chunde Li, Aurelius Omlin, Giuseppe Procopio, Satoshi Fukasawa, Ken-ichi Tabata, Se Hoon Park, Susan Feyerabend, Charles G. Drake, Haiyan Wu, Ping Qiu, Jeri Kim, Christian Poehlein, Johann Sebastian de Bono

METHODS

Whole-Exome DNA Sequencing. Whole-exome DNA sequences were aligned to reference human genome GRCh37 (Burrows-Wheeler Aligner), variants were detected using MuTect, DNA damage repair genes examined were ATM, ATR, BAP1, BARD1, BLM, BRAP, BRCA1, BRCA2, BRIP1, CDH1, CDK12, CENPQ, CHEK1, CHEK2, EPCAM1, ERCC1, ERCC2, ERCC3, ERCC4, ERCC6, FAM175A, FAM175B, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCQ, FANCI, FANCL, GEN1, HDAC2, MLH1, MLH3, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PIF1, PMS2, RAD51, RAD51B, RAD51C, RAD51D, RAD54L, RDM1, TP53, and XRCC2. Pathogenic or likely pathogenic mutations were defined as those that were predicted to result in protein loss—homozgyous deletions—or protein truncation—nonsense mutations, frameshift insertions or deletions, and splicing mutations at conserved splice donor/acceptor sites—except in the case of TP53, where known inactivation missense mutations were also coded as pathogenic. Sequence alterations not known to alter the encoded protein were denoted as variants of unknown significance.

Definitions of Study End Points and Censoring Rules for Time-to-Event End Points. Objective response rate was defined as the percentage of patients with confirmed complete or partial response. Disease control rate was defined as the percentage of patients with best overall response of stable disease for 6 months or longer or confirmed complete or partial response. Radiographic progression-free survival was defined as the time from the first day of study treatment to disease progression or death from any cause, whichever occurred first; data for patients who were alive and did not experience disease progression were censored at the time of last tumor assessment. Overall survival was defined as the time from the first day of study treatment to death from any cause; data for patients who were alive were censored at the time of last contact. The prostate-specific antigen response rate was defined as the percentage of patients with a 50% or greater reduction in the prostate-specific antigen level from baseline confirmed on an evaluation performed 3 weeks later or longer. Duration of response was defined as the time from first documented evidence of complete or partial response until progressive disease or death as a result of any cause, whichever occurred first, in patients with confirmed complete or partial response. Censoring rules for duration of response were as follows:

- Data for responders who were alive and without disease progression or new anticancer therapy were censored at the time of last tumor assessment.
- Data for responders who were alive and without disease progression but who started new anticancer therapy were censored at the time of last tumor assessment before the start of the new anticancer therapy.
- Data for responders who died or had disease progression after two or more missed adequate tumor assessments were censored at the time of last adequate tumor assessment before the two or more missed adequate tumor assessments.
<table>
<thead>
<tr>
<th>Response assessed per RECIST v1.1 by central radiology review</th>
<th>Cohort 1 (PD-L1 positive; n = 133)</th>
<th>Cohort 2 (PD-L1 negative; n = 66)</th>
<th>Cohort 3 (bone predominant; n = 59)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete response</td>
<td>2 (2)</td>
<td>0</td>
<td>—</td>
</tr>
<tr>
<td>Partial response</td>
<td>5 (4)</td>
<td>2 (3)</td>
<td>—</td>
</tr>
<tr>
<td>Stable disease of any duration</td>
<td>23 (17)</td>
<td>14 (21)</td>
<td>—</td>
</tr>
<tr>
<td>≥ 6-mo duration</td>
<td>6 (5)</td>
<td>4 (6)</td>
<td>—</td>
</tr>
<tr>
<td>Non-CR/non-PD* of any duration</td>
<td>0</td>
<td>0</td>
<td>22 (37)</td>
</tr>
<tr>
<td>≥ 6-mo duration</td>
<td>0</td>
<td>0</td>
<td>13 (22)</td>
</tr>
<tr>
<td>Progressive disease</td>
<td>79 (59)</td>
<td>42 (64)</td>
<td>32 (54)</td>
</tr>
<tr>
<td>Not evaluable†</td>
<td>4 (3)</td>
<td>1 (2)</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Not assessable‡</td>
<td>20 (15)</td>
<td>7 (11)</td>
<td>4 (7)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Response assessed per PCWG3-modified RECIST v1.1 by central radiology review</th>
<th>Cohort 1 (PD-L1 positive; n = 133)</th>
<th>Cohort 2 (PD-L1 negative; n = 66)</th>
<th>Cohort 3 (bone predominant; n = 59)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete response</td>
<td>2 (2)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Partial response</td>
<td>5 (4)</td>
<td>2 (3)</td>
<td>0</td>
</tr>
<tr>
<td>Stable disease of any duration</td>
<td>29 (22)</td>
<td>25 (38)</td>
<td>0</td>
</tr>
<tr>
<td>≥ 6-mo duration</td>
<td>10 (8)</td>
<td>10 (15)</td>
<td>0</td>
</tr>
<tr>
<td>Non-CR/non-PD* of any duration</td>
<td>0</td>
<td>0</td>
<td>35 (59)</td>
</tr>
<tr>
<td>≥ 6-mo duration</td>
<td>0</td>
<td>0</td>
<td>23 (39)</td>
</tr>
<tr>
<td>Progressive disease</td>
<td>71 (53)</td>
<td>30 (45)</td>
<td>19 (32)</td>
</tr>
<tr>
<td>Not evaluable†</td>
<td>6 (5)</td>
<td>2 (3)</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Not assessable‡</td>
<td>20 (15)</td>
<td>7 (11)</td>
<td>4 (7)</td>
</tr>
</tbody>
</table>

NOTE. Data presented as No. (%).
Abbreviations: CR, complete response; PCWG3, Prostate Cancer Working Group 3; PD, progressive disease; PD-L1, programmed cell death ligand 1.
*Patients without disappearance of all existing lesions or development of new lesions.
†Patients who had one or more postbaseline imaging assessment, none of which were evaluable for response.
‡Patients who did not undergo postbaseline imaging.
TABLE A3. Genomic Analysis of 50 DNA Damage Repair Genes in the Six Responders With Evaluable Whole-Exome Sequencing Data

<table>
<thead>
<tr>
<th>Patient 1 (cohort 1)</th>
<th>Patient 2 (cohort 1)</th>
<th>Patient 3 (cohort 2)</th>
<th>Patient 4 (cohort 1)</th>
<th>Patient 5 (cohort 1)</th>
<th>Patient 6 (cohort 1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATM splice site acceptor deletion (chr11_108121426-108121426_A_)</td>
<td>TP53 R273P substitution</td>
<td>BRCA2 V1176Gfs*8 insertion</td>
<td>NBN Q494P substitution†</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>BRCA2 A1162V substitution†</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDK12 G1461Afs* deletion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FANCA substitution† (chr16_89816312-89816312_T_C)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FANCD2 R263H substitution†</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MLH3 T930Qfs*35 deletion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RAD54L R511H substitution†</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NOTE. The following 50 DNA damage repair genes were examined: ATM, ATR, BAPI, BARD1, BLM, BRAP, BRCA1, BRCA2, BRIPI, CDH1, CDK12, CENPQ, CHEK1, CHEK2, EPCAM1, ERCC1, ERCC2, ERCC3, ERCC4, ERCC6, FAM175A, FAM175B, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCQ, FANCI, FANCL, GEN1, HDAC2, MLH1, MLH3, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PIF1, PMS2, RAD51, RAD51B, RAD51C, RAD51D, RAD54L, RDM1, TP53, and XRCC2.

†Variants of unknown significance.